After 10 days, IL-15-stimulated CIK cells showed enhanced killing of AML and lymphoma cell lines as well as primary acute myeloid and lymphoblastic leukemia cells in vitro and to a certain extent improved efficacy of CIK cell therapy compared to conventional DLI in patients with relapsing hematological malignancies after allogeneic HSCT [155]. Here, IL15 is linked to acute myeloid leukemia.